Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

150 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Multicentric phase II trial of gemcitabine plus epirubicin plus paclitaxel as first-line chemotherapy in metastatic breast cancer.
Cappuzzo F, Mazzoni F, Gennari A, Donati S, Salvadori B, Orlandini C, Cetto GL, Molino A, Galligioni E, Mansutti M, Tumolo S, Lucentini A, Valduga F, Bartolini S, Crinò L, Conte PF. Cappuzzo F, et al. Among authors: bartolini s. Br J Cancer. 2004 Jan 12;90(1):31-5. doi: 10.1038/sj.bjc.6601518. Br J Cancer. 2004. PMID: 14710202 Free PMC article. Clinical Trial.
Phase II trial of carboplatin and etoposide for patients with recurrent high-grade glioma.
Franceschi E, Cavallo G, Scopece L, Paioli A, Pession A, Magrini E, Conforti R, Palmerini E, Bartolini S, Rimondini S, Esposti RD, Crinò L. Franceschi E, et al. Among authors: bartolini s. Br J Cancer. 2004 Sep 13;91(6):1038-44. doi: 10.1038/sj.bjc.6602105. Br J Cancer. 2004. PMID: 15305187 Free PMC article. Clinical Trial.
Phase II study of gemcitabine plus oxaliplatin as first-line chemotherapy for advanced non-small-cell lung cancer.
Cappuzzo F, Novello S, De Marinis F, Franciosi V, Maur M, Ceribelli A, Lorusso V, Barbieri F, Castaldini L, Crucitta E, Marini L, Bartolini S, Scagliotti GV, Crinò L. Cappuzzo F, et al. Among authors: bartolini s. Br J Cancer. 2005 Jul 11;93(1):29-34. doi: 10.1038/sj.bjc.6602667. Br J Cancer. 2005. PMID: 15956971 Free PMC article. Clinical Trial.
A randomized phase II trial evaluating standard (50 mg/min) versus low (10 mg/min) infusion duration of gemcitabine as first-line treatment in advanced non-small-cell lung cancer patients who are not eligible for platinum-based chemotherapy.
Cappuzzo F, Novello S, De Marinis F, Selvaggi G, Scagliotti GV, Barbieri F, Maur M, Papi M, Pasquini E, Bartolini S, Marini L, Crinò L. Cappuzzo F, et al. Among authors: bartolini s. Lung Cancer. 2006 Jun;52(3):319-25. doi: 10.1016/j.lungcan.2006.03.004. Epub 2006 Apr 19. Lung Cancer. 2006. PMID: 16630670 Clinical Trial.
Role of gemcitabine in cancer therapy.
Toschi L, Finocchiaro G, Bartolini S, Gioia V, Cappuzzo F. Toschi L, et al. Among authors: bartolini s. Future Oncol. 2005 Feb;1(1):7-17. doi: 10.1517/14796694.1.1.7. Future Oncol. 2005. PMID: 16555971 Review.
HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients.
Cappuzzo F, Toschi L, Domenichini I, Bartolini S, Ceresoli GL, Rossi E, Ludovini V, Cancellieri A, Magrini E, Bemis L, Franklin WA, Crino L, Bunn PA Jr, Hirsch FR, Varella-Garcia M. Cappuzzo F, et al. Among authors: bartolini s. Br J Cancer. 2005 Dec 12;93(12):1334-40. doi: 10.1038/sj.bjc.6602865. Br J Cancer. 2005. PMID: 16288303 Free PMC article.
Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinib.
Cappuzzo F, Toschi L, Tallini G, Ceresoli GL, Domenichini I, Bartolini S, Finocchiaro G, Magrini E, Metro G, Cancellieri A, Trisolini R, Crino L, Bunn PA Jr, Santoro A, Franklin WA, Varella-Garcia M, Hirsch FR. Cappuzzo F, et al. Among authors: bartolini s. Ann Oncol. 2006 Jul;17(7):1120-7. doi: 10.1093/annonc/mdl077. Epub 2006 Apr 6. Ann Oncol. 2006. PMID: 16600976 Free article.
150 results